Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
Elurbide J, Colyn L, Latasa MU, Uriarte I, Mariani S, Lopez-Pascual A, Valbuena E, Castello-Uribe B, Arnes-Benito R, Adan-Villaescusa E, Martinez-Perez LA, Azkargorta M, Elortza F, Wu H, Krawczyk M, Schneider KM, Sangro B, Aldrighetti L, Ratti F, Casadei Gardini A, Marin JJG, Amat I, Urman JM, Arechederra M, Martinez-Chantar ML, Trautwein C, Huch M, Cubero FJ, Berasain C, G Fernandez-Barrena M, Avila MA.
Elurbide J, et al. Among authors: amat i.
Gut. 2024 Sep 11:gutjnl-2024-332998. doi: 10.1136/gutjnl-2024-332998. Online ahead of print.
Gut. 2024.
PMID: 39266051
Free article.